AI
FPRX

Analytic Investors’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Analytic Investors’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-4,844
Closed -$200K – 705
2016
Q2 		$200K Buy
+4,844
New +$211K ﹤0.01% 577

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Analytic Investors's FPRX Position: Q3 2016 in Review

Analytic Investors sold out of Five Prime Therapeutics, Inc. (FPRX) in Q3 2016, closing a stake of 4,844 shares — an estimated $200K sold.

Analytic Investors first reported a position in FPRX in Q2 2016 and held it in 1 quarter. The position peaked at $200K in Q2 2016. 176 funds tracked by Wall St. Rank hold FPRX as of Q3 2016.

  • Analytic Investors reported no remaining Five Prime Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
  • Analytic Investors sold 4,844 Five Prime Therapeutics, Inc. shares in Q3 2016, an estimated $200K.
  • Analytic Investors first reported a position in Five Prime Therapeutics, Inc. in Q2 2016 and held it in 1 quarter.
  • Analytic Investors's Five Prime Therapeutics, Inc. position peaked at $200K in Q2 2016.
  • 176 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q3 2016.

Based on Analytic Investors's 13F filing for Q3 2016, filed 14 Nov 2016.